More than 2.3 million people worldwide are diagnosed with breast cancer each year, and Delphi Diagnostics says the tests doctors lean on to plan their treatment are too blunt for the job.
The company’s answer is the Endocrine Activity Index, a genomic test that gauges how active endocrine signalling is inside a tumour. It is built for patients with Stage II-III breast cancer that is hormone receptor positive and HER2 negative.
What the score is meant to decide
Delphi says the reading helps sort out who gains most from a dose-intense chemotherapy regimen based on paclitaxel, and who should be offered a longer course of endocrine therapy after surgery. Just as important, in the company’s telling, is spotting the patients for whom a treatment would add nothing.
A second product, the Endocrine Activity Index Recurrence Risk, folds the genomic reading together with the tumour’s baseline features and the patient’s own risk factors to produce a prognosis. Delphi describes it as a consistent indicator of long-term outcomes in Stage II-III disease.
Two published papers sit behind the pitch. One, in the Journal of Clinical Oncology in January 2023, compared the Sensitivity to Endocrine Therapy Index with the 21-gene Breast Recurrence Score in the SWOG S8814 trial. The other, from 2025 and also in the Journal of Clinical Oncology, looked at adjuvant dose-dense chemotherapy in hormone receptor positive breast cancer.
Delphi is also working with GEICAM and Unicancer on a joint analysis aimed at personalising adjuvant chemotherapy in early breast cancer.
